The test is a 15-biomarker quantitative PCR panel used to stratify patients with Crohn's disease and ulcerative colitis based on the severity of their illness.
While the first task of the centers will be to digitize their workflows to improve efficiency, they also aim to eventually develop new AI-based analytical tools for diagnosing patients.
The UK government aims to create six centers specializing in digital pathology, medical imaging or both, working together through a framework agreement.
The privately held Cambridge, UK-based company announced earlier this month that it had raised an additional £11 million to support the commercialization of its platform.
The collaborators aim to show that Cytox' VariaTect SNP profiling array and an associated algorithm can effectively predict the presence of Alzheimer's pathology.
The company plans to use the funding to prepare for a clinical study of the test slated to begin later this year.
A total of 66 projects were awarded the funding as part of the Biomedical Catalyst 2016 funding.